Pharmaceutical Companies Seek to Balance Quality Assurance & Cost Reduction

Pharmaceutical Companies Seek to Balance Quality Assurance & Cost Reduction 
 
  
CHAPEL HILL, N.C., June 12 /PRNewswire/ -- Two-thirds of companies find that a vertical quality and compliance model effectively increases internal efficiencies compared to a horizontal model. However, according to a recent study by Best Practices, LLC's GLOBAL BENCHMARKING COUNCIL, having a single Q&C organization per function does not help reduce operating costs, an increasingly important challenge in today's economic landscape.


How efficient and effective are quality and compliance processes at your company?


Download a complimentary research briefing at http://www3.best-in-class.com/gr193.htm to view key study objectives, a list of benchmarked companies, selected key findings, commonly used quality and compliance management structures and their effectiveness, reorganization trends and more. This partner-driven primary research is an example of how we support quality executives with relevant metrics and best practices for strategic decision-making.


Recently Added Research for Partners include:


The Role of Regulatory Affairs in Preparing for NDA Interactions
Best Practices for Valuing Internal Consulting Organizations
M&A Integration Excellence: What Bio-Pharma Companies Need to Know
Skills, Capabilities and Competencies for Success in Regulatory Affairs
Safety and Risk Management in the Pharmaceutical Sector

 

Discuss your specific business dilemmas in a Guided Virtual Presentation of our decision support services with Elizabeth Winstead, director of solutions. Please sign up now at http://www3.best-in-class.com/gr179.htm to explore further the suite of research and networking opportunities available to you through a business partnership with the GLOBAL BENCHMARKING COUNCIL. For more information, contact her directly at 919.767.9259, [email protected]


Best Practices, LLC's GLOBAL BENCHMARKING COUNCIL (http://www3.best-in-class.com/gbc) is an innovative research, benchmarking and networking service for business executives in pharmaceutical and life sciences to promote top-line revenue growth, cost reduction and innovative problem-solving.


For more than a decade, executives have used GLOBAL BENCHMARKING COUNCIL competitive advantages, such as ready access to executives, fast-turnaround research efforts, expansive Best Practice Database and annual networking conferences to refine initiatives, request funding and allocate resources.

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i